跳转至内容
Merck

Y0000288

吡拉西坦

European Pharmacopoeia (EP) Reference Standard

别名:

2-氧代-1-吡咯烷乙酰胺, 吡拉西坦

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C6H10N2O2
CAS号:
分子量:
142.16
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

piracetam

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

2-8°C

SMILES字符串

NC(=O)CN1CCCC1=O

InChI

1S/C6H10N2O2/c7-5(9)4-8-3-1-2-6(8)10/h1-4H2,(H2,7,9)

InChI key

GMZVRMREEHBGGF-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Piracetam EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

相关产品

储存分类代码

11 - Combustible Solids

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

A A Al Hajeri et al.
The Cochrane database of systematic reviews, (2)(2), CD006111-CD006111 (2007-04-20)
Sickle cell disease is one of the most common genetic disorders. Sickle cell crises in which irregular and dehydrated cells contribute to blocking of blood vessels are characterised by episodes of pain. Treatment is mainly supportive and symptomatic. In vitro
S Ricci et al.
The Cochrane database of systematic reviews, (2)(2), CD000419-CD000419 (2006-04-21)
Piracetam has neuroprotective and antithrombotic effects which may help to reduce death and disability in people with acute stroke. The objective of this review was to assess the effects of piracetam in acute presumed ischaemic stroke. We searched the Cochrane
Fulvio Gualtieri et al.
Current pharmaceutical design, 8(2), 125-138 (2002-01-29)
Cognition enhancers are drugs able to facilitate attentional abilities and acquisition, storage and retrieval of information, and to attenuate the impairment of cognitive functions associated with head traumas, stroke, age and age-related pathologies. Development of cognition enhancers is still a
G Justus Hofmeyr et al.
The Cochrane database of systematic reviews, 6(6), CD001064-CD001064 (2012-06-15)
Piracetam is thought to promote the metabolism of brain cells when they are hypoxic. It has been used to prevent adverse effects of fetal distress. The objective of this review was to assess the effects of piracetam for suspected fetal
Stefano Ricci et al.
The Cochrane database of systematic reviews, 9(9), CD000419-CD000419 (2012-09-14)
Piracetam has neuroprotective and antithrombotic effects that may help to reduce death and disability in people with acute stroke. This is an update of a Cochrane Review first published in 1999, and previously updated in 2006 and 2009. To assess

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门